IDE161 not checked

IDEAYA Biosciences

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3, Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer and 4 more
Main trialPhase 1/2
“This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.”In the company’s words, NCT07174583 on ClinicalTrials.gov

Other drugs for Small-cell Lung Cancer

All 118 drugs for Small-cell Lung Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Jul 2029 A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Phase 1Active, not recruiting Oct 2026 A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IDE161

Following is part of Solo: you see every change to IDE161 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in